文献速递呼吸道感染呼吸危重症与机械通气

静脉皮质类固醇冲击治疗优于低剂量皮质类固醇治疗重症COVID-19吗?

Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19?
PubMed 文献 · Eur Respir J · 2022-10-20

本文探讨静脉皮质类固醇冲击治疗是否优于低剂量皮质类固醇治疗重症COVID-19。地塞米松6 mg/日已被RECOVERY试验证实可降低需要补氧或机械通气的住院COVID-19患者28天死亡率,随机对照试验的荟萃分析也证实了该结果。这些随机对照试验中使用的皮质类固醇剂量为低剂量(地塞米松6 mg/日)或中等剂量(地塞米松最高20 mg/日)。

要点

  • 地塞米松6 mg/日可降低需要补氧或机械通气的住院COVID-19患者28天死亡率。
  • 随机对照试验的荟萃分析证实了RECOVERY试验关于低剂量皮质类固醇获益的结果。
  • 已发表的随机对照试验中皮质类固醇剂量为低剂量或中等剂量,未涉及冲击治疗。

核心结论

  • 静脉皮质类固醇冲击治疗是否优于低剂量皮质类固醇治疗重症COVID-19尚待明确。

主要发现

  • RECOVERY试验显示地塞米松6 mg/日可降低需要补氧或机械通气的住院COVID-19患者28天死亡率。
  • 随机对照试验的荟萃分析证实了RECOVERY试验的结果。
  • 已发表的随机对照试验中皮质类固醇剂量为低剂量(地塞米松6 mg/日)或中等剂量(地塞米松最高20 mg/日)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Corticosteroids were the first drugs proven to reduce mortality in Covid-19. In June 2020, the RECOVERY group announced the results of their seminal trial showing dexamethasone 6 mg per day was able to reduce 28-day mortality in hospitalized patients with Covid needing supplemental oxygen or mechanical ventilation [1]. Meta-analysis from randomized controlled trials (RCT) in Covid-19 patients confirmed RECOVERY results [2]. In those RCTs, corticosteroid doses were low (dexamethasone 6 mg per day) or intermediate (dexamethasone up to 20mg per day).

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Veiga VC, Cavalcanti AB. Are intravenous corticosteroid pulses superior to low dose corticosteroids in patients with severe COVID-19? Eur Respir J. 2022. PMID: 35777764. doi:10.1183/13993003.01220-2022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。